Thousands with chronic liver cirrhosis can be saved or lead improved lives now

Zurich, Switzerland, 4. December 2019 Chronic liver cirrhosis, mainly caused by Hepatitis B and C, has for long been a huge problem without any option for treatment. However, Baermed Liver Cell Technologies has developed the HMI treatment, which are "mini-livers" retrieved from a patient’s own body. The addressable market for the HMI treatment is calculated at over $25 billion in Asia and Europe alone. This treatment has been fully developed and is currently the only option (apart from liver transplantation) to treat liver cirrhosis. Partnerships in Asia and Europe are being evaluated by Strategic Swiss Partners and Baermed to complete phase II studies, register the matrix and make the treat

Featured Posts
Recent Posts
Follow Us

Strategic Swiss Partners AG,

Bahnhofstrasse 10 / Börsenstrasse 18, 8001 Zürich  SWITZERLAND  |   +41 44 980 8000 

Copyright   ©   Strategic Swiss Partners AG 2019